Lantern Pharma (Nasdaq:LTRN) - Hisse Senedi Fiyatı, Haberler ve Analizler

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

LTRN Stoklara Genel Bakış

Klinik aşamada bir biyoteknoloji şirketi olan Lantern Pharma Inc. ilaç geliştirme sürecini kolaylaştırmak için yapay zeka, makine öğrenimi ve genomik verilere odaklanmaktadır.

Şirket hakkında

LTRN temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Risk Analizi

Geliri 1 milyon ABD dolarından az ( $0 )

Önümüzdeki 3 yıl boyunca kazançların yılda ortalama 8% oranında düşmesi öngörülüyor

Anlamlı bir piyasa değeri yok ( $40M )

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

+ 1 daha fazla risk

Lantern Pharma Inc. Rakipler

Fortress Biotech

NasdaqCM:FBIO

US$43.1m

Kezar Life Sciences

NasdaqCM:KZR

US$60.2m

Achilles Therapeutics

NasdaqGS:ACHL

US$41.9m

vTv Therapeutics

NasdaqCM:VTVT

US$42.7m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Lantern Pharma
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$3.77
52 Haftanın En Yüksek Seviyesi	US$11.99
52 Haftanın En Düşük Seviyesi	US$2.38
Beta	1.55
11 Aylık Değişim	4.43%
3 Aylık Değişim	-13.93%
1 Yıllık Değişim	20.83%
33 Yıllık Değişim	-65.85%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-74.78%

Son Haberler & Güncellemeler

Lantern Pharma (NASDAQ:LTRN) Is In A Good Position To Deliver On Growth Plans

Jun 12

Recent updates

Here's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation

Dec 19

We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

Sep 02

Lantern Pharma gets FDA nod to start mid-stage study of LP-300 in lung cancer

Jul 14

Companies Like Lantern Pharma (NASDAQ:LTRN) Are In A Position To Invest In Growth

May 20

Here's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation

Feb 02

We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

Oct 13

Lantern Pharma: Consider A Speculative Long-Term Investment In This AI Drug Discoverer

Aug 24

Lantern Pharma: Drug Recycling With AI

Jun 08

We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate

May 05

Lantern Pharma reports Q1 results

May 03

Here's What Lantern Pharma Inc.'s (NASDAQ:LTRN) Shareholder Ownership Structure Looks Like

Feb 19

Lantern Pharma announces antibody drug conjugate tie-up with Califia Pharma

Jan 04

Who Has Been Buying Lantern Pharma Inc. (NASDAQ:LTRN) Shares?

Dec 28

Lantern: Early Stage 'Smart Drug' Discovery Company

Nov 25

Hissedar Getirileri

	LTRN	US Biotechs	US Pazar
7D	-0.1%	-0.5%	0.3%
1Y	20.8%	18.0%	32.4%

Getiri vs. Endüstri: LTRN geçen yıl % 17.6 oranında getiri sağlayan US Biotechs sektörünü aştı.

Getiri vs Piyasa: LTRN geçen yıl % 34.1 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is LTRN's price volatile compared to industry and market?
LTRN volatility
LTRN Average Weekly Movement	10.8%
Biotechs Industry Average Movement	10.0%
Market Average Movement	6.4%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: LTRN hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: LTRN 'nin haftalık oynaklığı ( 11% ) geçen yıl boyunca sabit kaldı, ancak hala US hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2013	21	Panna Sharma	www.lanternpharma.com

Klinik aşamada bir biyoteknoloji şirketi olan Lantern Pharma Inc. ilaç geliştirme sürecini kolaylaştırmak için yapay zeka, makine öğrenimi ve genomik verilere odaklanmaktadır. Ürün hattı, küçük hücreli dışı akciğer kanseri adenokarsinomu olan hiç sigara içmemiş kişiler için kombinasyon tedavisinde faz 2 klinik çalışmada olan LP-300; pankreas, meme, mesane ve akciğer kanserleri ve glioblastoma ve diğer merkezi sinir sistemi kanserleri gibi solid tümör tedavisi için faz 1 klinik çalışmada olan LP-184; ve mantle hücreli lenfoma ve çift vuruşlu lenfoma dahil olmak üzere Hodgkin dışı lenfomaların tedavisi için faz 1 klinik çalışmada olan LP-284'ten oluşmaktadır. Şirket, glioblastom, beyin metastazları, atipik teratoid rabdoid tümörler ve pediatrik nadir hastalıkların tedavisi için klinik öncesi geliştirme aşamasında olan STAR-001'i geliştirmektedir.

Lantern Pharma Inc. Temel Bilgiler Özeti

Lantern Pharma'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
LTRN temel i̇stati̇sti̇kler
Piyasa değeri	US$38.75m
Kazançlar(TTM)	-US$17.75m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-2.3x

F/K Oranı

LTRN aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
LTRN gelir tablosu (TTM)
Gelir	US$0
Gelir Maliyeti	US$0
Brüt Kâr	US$0
Diğer Giderler	US$17.75m
Kazançlar	-US$17.75m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-1.65
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	0%

LTRN uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

LTRN Stoklara Genel Bakış

Ödüller

Risk Analizi

Lantern Pharma Inc. Rakipler

NasdaqCM:FBIO

US$43.1m

NasdaqCM:KZR

US$60.2m

NasdaqGS:ACHL

US$41.9m

NasdaqCM:VTVT

US$42.7m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Lantern Pharma Highlights Promising Preclinical Results of LP-184'S Synergy with Checkpoint Inhibitors & Sensitizing Tumors That Are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson At Immuno-Oncology Summit 2024

Lantern Pharma Inc. to Report Q2, 2024 Results on Aug 08, 2024

Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for Use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184

Lantern Pharma Inc.(NasdaqCM:LTRN) dropped from Russell 3000E Value Index

Lantern Pharma (NASDAQ:LTRN) Is In A Good Position To Deliver On Growth Plans

Lantern Pharma Inc. to Report Q1, 2024 Results on May 09, 2024

Recent updates

Lantern Pharma Highlights Promising Preclinical Results of LP-184'S Synergy with Checkpoint Inhibitors & Sensitizing Tumors That Are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson At Immuno-Oncology Summit 2024

Lantern Pharma Inc. to Report Q2, 2024 Results on Aug 08, 2024

Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for Use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184

Lantern Pharma Inc.(NasdaqCM:LTRN) dropped from Russell 3000E Value Index

Lantern Pharma (NASDAQ:LTRN) Is In A Good Position To Deliver On Growth Plans

Lantern Pharma Inc. to Report Q1, 2024 Results on May 09, 2024

Lantern Pharma Inc., Annual General Meeting, Jun 13, 2024

Lantern Pharma Inc. Receives Regulatory Approval to Expand Harmonic Clinical Trial for Non-Small Cell Lung Cancer in Never-Smakers into Japan and Taiwan

Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, Lp-284

Lantern Pharma Inc. to Report Q4, 2023 Results on Mar 18, 2024

Lantern Pharma Inc. Announces Series of Important Milestones Related to the Development, Size, and Advancement of RADR

We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

Lantern Pharma Advances Unique ADC Program Across Multiple Solid Tumor Cancers

New minor risk - Share price stability

We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate

Lantern Pharma Inc. to Report Q3, 2023 Results on Nov 08, 2023

Lantern Pharma Inc. Announces the Death of Dr. Franklyn Prendergast, a Director of the Company

Lantern Pharma Inc. Announces Publication in Clinical Cancer Research Highlighting the Enhanced Efficacy of Lp-184 in Glioblastoma

Lantern Pharma Inc. Announces First Patient Dosed in the Phase 1 Study for LP-184 in Advanced Solid Tumors

Lantern Pharma Receives IND Clearance from FDA Enabling Phase 1 Initiation for Drug Candidate LP-284 in Non-Hodgkin’s Lymphomas

Lantern Pharma Inc. to Present Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-284 in Non-Hodgkin's Lymphomas at the Society of Hematologic Oncology Annual Meeting

Lantern Pharma Inc. Expands AI Capabilities of RADR(R) Platform to Accelerate the Clinical Development of Immune Checkpoint Inhibitors

Lantern Pharma (NASDAQ:LTRN) Is In A Good Position To Deliver On Growth Plans

Oncotarget Publishes New Data by Lantern Pharma Further Supporting Clinical Advancement of LP-284, A Novel Synthetic Lethal Drug Candidate for Non-Hodgkin's Lymphomas

Lantern Pharma Receives FDA Clearance of IND Application for Drug Candidate LP-184 in Solid Tumors

Lantern Pharma Leverages AI Platform, RADR®, to Develop Breakthrough Antibody Drug Conjugates (ADCs) in Collaboration with Bielefeld University

We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

Lantern Pharma Inc. Further Enhances Capabilities of its AI Drug Discovery Platform, RADR®, with Product Development Roadmap for the Development of Antibody Drug Conjugates

Lantern Pharma Inc. Receives Pre-IND Feedback from the FDA

Here's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation

Lantern Pharma Inc. Announces Positive New Data for Its Drug Candidate LP-284 for Mantle Cell Lymphoma

Lantern Pharma Inc. Announces Development of Drug Candidate LP-184 for Triple Negative Breast Cancer (TNBC) at the San Antonio Breast Cancer Symposium (SABCS)

Lantern Pharma Announces Positive Data Highlighting the Anti-Tumor Potency of Drug Candidate Lp-184 for Glioblastoma

Price target decreased to US$18.50

Lantern Pharma Inc. to Report Q3, 2022 Results on Nov 07, 2022

Lantern Pharma Inc. to Present Positive Preclinical Data on the Efficacy of LP-284 for Mantle Cell Lymphoma at the Society of Hematologic Oncology Annual Meeting

We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

Lantern Pharma Receives Food and Drug Administration Authorization to Initiate its Phase 2 Clinical Trial, Harmonic, for LP-300 in Never Smokers with Non-Small Cell Lung Cancer

Lantern Pharma gets FDA nod to start mid-stage study of LP-300 in lung cancer

Price target decreased to US$26.00

Companies Like Lantern Pharma (NASDAQ:LTRN) Are In A Position To Invest In Growth

Lantern Pharma Inc. Announces Leslie W. Kreis, Jr. Not to Stand for Reelection as A Director

Lantern Pharma Inc. to Report Q1, 2022 Results on May 03, 2022

Here's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation

Lantern Pharma Receives Rare Pediatric Disease and Orpan Drug Designations for Lp-184 for the Treatment of Atypical Teratoid Rhabdoid Tumor

Lantern Pharma Presents Positive Data on the Effectiveness of LP-284 in Hematologic Cancers at the 63rd American Society of Hematology

Lantern Pharma Inc. (NasdaqCM:LTRN) announces an Equity Buyback for $7 million worth of its shares.

We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

Price target increased to US$29.50

Lantern Pharma: Consider A Speculative Long-Term Investment In This AI Drug Discoverer

Lantern Pharma: Drug Recycling With AI

We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate

Lantern Pharma reports Q1 results

Lantern Pharma Announces That RADR® Has Exceeded 4.6 Billion Datapoints

Lantern Pharma Inc. Announces Publication Detailing Preclinical Results of Drug Candidate, LP-184, in a Spectrum of Drug-Resistant Lung Cancers in the Journal Oncotarget

Lantern Pharma Inc. Announces Filing of Seven Patent Applications Globally on Novel DNA-Damaging Agent with Anticancer Properties

Here's What Lantern Pharma Inc.'s (NASDAQ:LTRN) Shareholder Ownership Structure Looks Like

Lantern Pharma Inc. has completed a Follow-on Equity Offering in the amount of $60.00001 million.

New 90-day low: US$14.51